The U.S. Food and Drug Administration has cleared the start of clinical trial testing of KT-621, Kymera Therapeutics’ oral therapy for chronic obstructive pulmonary disease (COPD) and other diseases marked by type 2 inflammation. KT-621 is designed to target STAT6, a protein involved in type 2 inflammation, which is marked by high blood counts of […] The post KT-621, potential oral medication for COPD, cleared for human trials appeared first on COPD News Today ..read more

I usually come away from my yearly wellness appointment feeling secure in my future, even though I have chronic obstructive pulmonary disease (COPD). That’s not the case this year; in fact, some of the results worried me. First, I learned that my B12 levels are too high and my iron level is normal. Yet I’m still […] The post My annual wellness visit has raised new health questions appeared first on COPD News Today ..read more

Ohtuvayre (ensifentrine), an inhaled therapy approved in the U.S. earlier this year for adults with chronic obstructive pulmonary disease (COPD), has been found to safely and effectively lead to clinical improvements among COPD patients regardless of disease severity, smoking history, and chronic bronchitis history. Chronic bronchitis is a common form of COPD marked by lung inflammation, […] The post Ohtuvayre effective across key patient subgroups: ENHANCE trials appeared first on COPD News Today ..read more

Dry-powder corticosteroid inhalers, or those designed to have a low impact on climate, are as effective as those based on pressurized, metered doses at reducing the risk of poor outcomes in people with both chronic obstructive pulmonary disease (COPD) and asthma. A large study in Denmark found the two inhalers posed comparable risks for hospitalizations […] The post Low climate-impact inhalers as effective as pressurized ones: Study appeared first on COPD News Today ..read more

This year I’ve realized that those of us with chronic obstructive pulmonary disease (COPD) may need help accomplishing essential tasks around the home, such as yard work and housework. Maintaining our blood oxygen saturation above 88% is necessary to keep our body functioning; anything below that is considered to be severe hypoxemia. When I had […] The post Learning how to ask for help was key to living better with COPD appeared first on COPD News Today ..read more

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with poorly controlled chronic obstructive pulmonary disease (COPD) and high counts of immune cells called eosinophils. Elevated eosinophils are a marker of type 2 inflammation, which is thought to contribute to COPD-related lung inflammation. The approval comes […] The post FDA approves Dupixent for adults with poorly controlled COPD appeared first on COPD News Today ..read more

The voice of people with chronic obstructive pulmonary disease (COPD) becomes more pitched and sounds breathy or hoarse at the early stages of disease exacerbations, which are episodes when symptoms suddenly worsen, according to a pilot study where 28 patients were asked to record their voices every day for about three months. The results were […] The post Voice changes may enable early detection of COPD exacerbations appeared first on COPD News Today ..read more

Many of us with chronic obstructive pulmonary disease (COPD) have received medical devices to help with our breathing. At first, it seemed to me that some of these devices worked better than others. But after gaining experience with them, I think that impression was based on the fact that perhaps I wasn’t using them correctly. […] The post 3 medical devices that help me with COPD management appeared first on COPD News Today ..read more

Adding GSK’s mepolizumab to standard inhaled treatment reduces the frequency of moderate to severe exacerbations in chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation, which contributes to lung inflammation. That’s according to top-line data from a Phase 3 clinical trial called MATINEE (NCT04133909) announced by GSK in a company press release. The study tested mepolizumab […] The post Mepolizumab reduces exacerbations in COPD with type 2 inflammation appeared first on COPD News Today ..read more

I’m dealing with a new symptom of my chronic obstructive pulmonary disease (COPD): excess mucus. It has to be expelled, since I have trouble coughing it up on my own. That’s why my doctor wanted me to take the expectorant Mucinex (guaifenesin) twice a day. Mucinex, like other expectorants, works by thinning the mucus so […] The post When a COPD symptom changes our routines, we must adapt appeared first on COPD News Today ..read more